B
Bull
Bull · 25%CKPT
$5.37
シナリオ価格
$4.260
+0.030 (+0.71%)終値時点
Loading chart…
- High
- 4.280
- Open
- 4.240
- VWAP
- 4.26
- Vol
- 8.67M
- Mkt Cap
- 75.91M
- Low
- 4.230
- Amount
- 36.89M
- EV/EBITDA, TTM
- 0.55
Checkpoint Therapeutics, Inc. is a commercial-stage immunotherapy and targeted oncology company focused on the acquisition, development and commercialization of novel treatments for patients with solid tumor cancers. Its product candidates include UNLOXCYTTM (cosibelimab-ipdl) for the treatment of adults with metastatic cSCC or locally advanced cSCC who are not candidates for curative surgery or curative radiation. Additionally, the Company is engaged in evaluating its lead investigational small-molecule, targeted anti-cancer agent, olafertinib, a third-generation epidermal growth factor receptor (EGFR) inhibitor, as a potential new treatment for patients with EGFR mutation-positive non-small cell lung cancer.
Analyst Ratings (1)
+1.64% upside
Buy
1 Buy
0 Hold
0 Sell
Current: 4.26
安値
4.10
平均
4.33
高値
4.80
D. Boral Capital
Strong Buy
$4.8
2025-03-31
D. Boral Capital
2025-03-31
目標株価
$4.8
Strong Buy
HC Wainwright & Co.
Hold
$4.1
2025-03-11
HC Wainwright & Co.
2025-03-11
目標株価
$4.1
Hold
D. Boral Capital
Strong Buy
$4.8
2025-03-10
D. Boral Capital
2025-03-10
目標株価
$4.8
Strong Buy
Lake Street
Hold
$4.1
2025-03-10
Lake Street
2025-03-10
目標株価
$4.1
Hold
D. Boral Capital
Strong Buy
$9
2025-01-13
D. Boral Capital
2025-01-13
目標株価
$9
Strong Buy
バリュエーション指標
The current forward P/E ratio for Checkpoint Therapeutics Inc (CKPT) is -24.48, compared to its 5-year average forward P/E of -5.63.
Alphio AI Price Scenarios for CKPT
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
イベントタイムライン
ニュース
5.010-08Yahoo FinanceForecast Report on the Cutaneous Squamous Cell Carcinoma Market (2025-2035) Featuring Regeneron Pharmaceuticals, Sanofi, Merck & Co., Checkpoint Therapeutics, Incyte, and Sirnaomics
9.505-15NewsfilterFortress Biotech Reports First Quarter 2025 Financial Results and Recent Corporate Highlights
5.005-15NASDAQ.COMFund Update: BARCLAYS PLC opened a $5.2M position in $CKPT stock
9.505-13NewsfilterCheckpoint Therapeutics Reports First Quarter Financial Results and Recent Corporate Updates
7.004-30GlobenewswireSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates OPTN, COEP, SWTX, CKPT on Behalf of Shareholders
CKPT FAQ — answered by Alphio AI
Checkpoint Therapeutics, Inc. is a commercial-stage immunotherapy and targeted oncology company focused on the acquisition, development and commercialization of novel treatments for patients with solid tumor cancers. Its product candidates include UNLOXCYTTM (cosibelimab-ipdl) for the treatment of adults with metastatic cSCC or locally advanced cSCC who are not candidates for curative surgery or curative radiation. Additionally, the Company is engaged in evaluating its lead investigational small-molecule, targeted anti-cancer agent, olafertinib, a third-generation epidermal growth factor receptor (EGFR) inhibitor, as a potential new treatment for patients with EGFR mutation-positive non-small cell lung cancer. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
1 analysts cover CKPT: 1 rate it Buy, 0 Hold and 0 Sell. The average price target is 4.33.
本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。